Plasma vitronectin concentrations in patients with chronic hepatitis C treated with interferon alpha

Clinica Chimica Acta

Volumn 261, Issue 1, 1997, Pages 81-90

  Yamada, Sadako ^a   Suou, Takeaki ^a   Kawasaki, Hironaka ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Chronic hepatitis C; Interferon; Vitronectin

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA INTERFERON; COLLAGEN TYPE 3; COLLAGEN TYPE 7; HEPATITIS C ANTIBODY; PROCOLLAGEN; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; VIRUS RNA; VITRONECTIN;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HUMAN; IMMUNOTHERAPY; INTRAMUSCULAR DRUG ADMINISTRATION; LABORATORY TEST; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; VIRUS HEPATITIS;

ALANINE TRANSAMINASE; COLLAGEN; FEMALE; HEPATITIS C; HEPATITIS, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROCOLLAGEN; RANDOM ALLOCATION; SENSITIVITY AND SPECIFICITY; SERUM ALBUMIN; VITRONECTIN;

HEPATITIS C VIRUS;

EID: 0030910626     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(96)06503-5     Document Type: Article

References (27)

1. Suzuki S, Pierschbacher MD, Hayman EG, Nguyen K, Ohgem N, Ruoslahti E. Domain structure of vitronectin. J Biol Chem 1984;259:15307-15314.
2. Barnes DW, van der Bosch J, Masui H, Miyazaki K, Sato G. The culture of human tumor cells in serum-free medium. Methods Enzymol 1981;79:368-369.
3. Tshopp J, Masson D, Schafer S, Peitsch M, Preissner KT. The heparin binding domain of S-protein/vitronectin binds to complement components C7, C8 and C9 and perform from cytolytic T-cells and inhibits their lytic activities. Biochemistry 1988;27:4103-4109.
4. Jenne D, Stanley KK. Molecular cloning of S-protein, a link between complement, coagulation and cell substrate adhesion. EMBO J 1985;4:3153-3157.
5. Kobayashi J, Yamada S, Kawasaki H. Distribution of vitronectin in plasma and liver tissue: relationship to chronic liver disease. Hepatology 1994;20:1412-1417.
6. Inuzuka S, Ueno T, Torimura T et al. vitronectin in liver disorders: Biochemical and immunohistochemical studies. Hepatology 1992;15:629-636.
7. Yamada S, Kobayashi J, Murawaki N, Suou T, Kawasaki H. Collagen-binding activity of plasma vitronectin in chronic liver disease. Clin Chim Acta 1996; 252:95-103.
8. Hopf U, Moller B, Kuther D et al. Long-term follow up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). J Hepatol 1990;10:69-76.
9. Kiyosawa K, Sodeyama T, Tanaka E et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology 1990;12:671-675.
10. Di Biscegli AM, Maartin P, Kassianides C et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized doubleblind, placebo-controlled trial. N Engl J Med 1989;321:1506-1510.
11. Yoshioka K, Kakumu S, Wakita T et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-α therapy: Relationship to genotypes of hepatitis C virus. Hepatology 1992;16:293-299.
12. Hagiwara H, Hayashi N, Mita E et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993;104:877-883.
13. Capra F, Casaril M, Gabrielli GB et al. α-interferon in the treatment of chronic viral hepatitis effects on fibrogenesis serum markers. J Hepatol 1993;18:112-118.
14. Suou T; Hosho K. Kishimoto Y, Horie Y, Kawasaki H. Long-term decrease in serum N-terminal propeptide of type III procollagen in patients with chronic hepatitis C treated with interferon alfa. Hepatology 1995;22:426-431.
15. Hiramatsu N, Hayashi N, Kasahara A et al. Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha. J Hepatol 1995;22:135-142.
16. Knodell RG, Ishak HG, Blak WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-435.
17. Akama T, Yamada KM, Seno N et al. Immunological characterization of human vitronectin and its binding to glycosaminoglycans. J Biochem 1986;100:1343-1351.
18. Yamada S, Suou T, Kawasaki H, Yoshikawa N. Clinical significance of serum 7S collagen in various liver diseases. Clin Biochem 1992;25:467-470.
19. Davis GL. Prediction of response to interferon treatment of chronic hepatitis C. J Hepatol 1994;21:1-3.
20. Preissner KT. Structure and biological role of vitronectin. Annu Rev Cell Biol 1991;7;275-310.
21. Seiffert D, Keeton M, Eguchi N, Sawdey M, Loskutoff DJ. Detection of vitronectin mRNA in tissues and cells of the mouse. Proc Natl Acad Sci USA 1991;88:9402-9406.
22. Czaja MJ. Weiner FR, Eghbali M, Giambrone M, Eghbali M, Zern MA. Differential effects of γ-interferon on collagen and fibronectin gene expression. J Biol Chem 1987;262:13 348-13 351.
23. Czaja MJ, Weiner FR, Takahashi S et al. γ-Interferon treatment inhibits collagen deposition in murine schistosomiasis. Hepatology 1989;10:795-800.
24. Duncan MR, Berman B. Differential regulation of glycosaminoglycan, fibronectin, and collagenase production in cultured human dermal fibroblasts by interferon-alpha, -beta, and -gamma. Arch Dermatol Res 1989;281:11-18.
25. Varga J, Olsen A, Herhal J, Constantine G, Rosenbloom J, Jimenez SA. Interferon-γ reverses the stimulation of collagen but not fibronectin gene expression by transforming growth factor-β in normal human fibroblasts. Eur J Clin Invest 1990;20:487-493.
26. Ramadori G, Knittel T, Odenthal M, Schwogler S, Neubauer K, Meyer zum Buschenfelde K. Synthesis of cellular fibronectin by rat liver fat-storing (Ito) cells: regulation by cytokines. Gastroenterol 1992;103:1313-1321.
27. Seiffert D, Geisterfer M, Gauldie J, Young E, Podor TJ. IL-6 stimulates vitronectin gene expression in vivo. J Immunol 1995;155:3180-3185.